• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

NHS Makes GBP200 Non-Drug Hypertension Treatment Device Available on Prescription

LONDON, February 1, 2012/PRNewswire/ -- From today, an innovative non-drug, non-invasive treatment for high blood pressure will be made available to all hypertensive patients on NHS prescription. RESPeRATE is an interactive respiratory modulation device clinically-proven to lower blood pressure. When used for just 15 minutes a day, at least four times a week, RESPeRATE has demonstrated a significant, all-day blood pressure reduction beyond that seen with concurrent medication and lifestyle modification such as diet and exercise.

The NHS decision to make the GBP200 medical device available to patients on prescription [at the standard prescription charge of GBP7.40] is a clear reflection of the Department of Health's belief in RESPeRATE's potential as a new treatment option.

Dr Benjamin Gavish, inventor of RESPeRATE and Chief Scientist of InterCure (manufacturer of RESPeRATE), said: "We are delighted that patients in the UK can now obtain RESPeRATE on prescription. We hope that this pioneering move by the NHS to set up a new device category to supplement the currently available treatment options for hypertension will encourage GPs to integrate RESPeRATE into their hypertension standard of care."

High blood pressure affects over 16 million people in the UK and is the direct cause of half of all strokes and heart attacks in the country. Failure to control blood pressure to target levels results in over 60,000 unnecessary deaths every year. Despite many recent advances in the medical treatment of hypertension and public health campaigns aimed at highlighting awareness of the dangers of high blood pressure, it remains a significant public health problem in the UK.

RESPeRATE is most likely to be initially prescribed for patients aged 65+ with not-yet-at-target blood pressure - in spite of medication, those who have diabetes with hypertension and those who either refuse medication or suffer side effects with current medications. The good news is that there are no known contraindications for, and have been no adverse reactions to the use of RESPeRATE.

image description image description


				

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Tara Fields, Classified Sales Manager
    (800) 237-7285, ext. 259

vdm Blogs

EVAR found superior to Open AAA Repair for long-term survival in Medicare patients: Another nail in open surgery’s coffin?

Frank J Criado MD FACS FSVM

Aneurysms and Cancer: Which comes first in the endovascular era?

Ross Milner MD FACS

What is the best therapy when we compare current data for revascularization of the SFA?

Lawrence A. Garcia MD

When a Patient Presents with an Ulcer, Take a Careful History

Richard R. Heuser MD FACC FACP FESC FSCAI

Long-term results with bare-metal LifeStent in the SFA: Is this bad news for DES technologies?

Frank J Criado MD FACS FSVM
more »

Vascular Newswire

  • Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
    Thu, 05/17/12 - 10:22am
  • Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
    Wed, 05/16/12 - 9:26am
  • Hospital Mortality Rates for Cardiovascular Revascularization Patients Varies Significantly by State
    Tue, 05/15/12 - 9:31am
  • Boston Scientific Announces CE Mark and European Launch of Innova Self-expanding Bare-metal Stent System
    Mon, 05/14/12 - 12:07pm
more »

Clinical Events Calendar

  • EuroPCR 2012
    Tue, 05/15/2012 - Fri, 05/18/2012
    Paris, France
  • International Vein Congress (IVC) 2012
    Thu, 05/31/2012 - Sun, 06/03/2012
    Miami Beach, FL, United States
  • New Cardiovascular Horizons (NCVH)
    Wed, 06/06/2012 - Sat, 06/09/2012
    New Orleans, LA, United States
more »

Poll

The current focus to decrease the profile size of aortic stent-grafts: :
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications